Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

LTRN

Lantern Pharma Inc

Apr 16 • 09:37AM ET

5.72

Dollar change -0.25
Percentage change -4.18	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF MEDX IWC AVSC DFAC DCOR

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.47	Insider Own	26.83%	Shs Outstand	10.72M	Perf Week	-26.28%
Market Cap	61.44M	Forward P/E	-	EPS next Y	-1.88	Insider Trans	-19.47%	Shs Float	7.86M	Perf Month	-34.25%
Income	-15.96M	PEG	-	EPS next Q	-0.43	Inst Own	10.90%	Short Float	5.36%	Perf Quarter	46.30%
Sales	0.00M	P/S	-	EPS this Y	-38.32%	Inst Trans	0.92%	Short Ratio	1.41	Perf Half Y	73.88%
Book/sh	3.82	P/B	1.50	EPS next Y	7.38%	ROA	-31.15%	Short Interest	0.42M	Perf Year	13.73%
Cash/sh	3.85	P/C	1.49	EPS next 5Y	-	ROE	-32.93%	52W Range	2.38 - 11.99	Perf YTD	33.66%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-39.81%	ROI	-38.96%	52W High	-52.29%	Beta	1.51
Dividend TTM	-	Quick Ratio	16.18	Sales past 5Y	0.00%	Gross Margin	-	52W Low	140.36%	ATR (14)	1.01
Dividend Ex-Date	-	Current Ratio	16.18	EPS Y/Y TTM	-12.02%	Oper. Margin	0.00%	RSI (14)	39.21	Volatility	11.59% 15.48%
Employees	21	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	2.00	Target Price	22.00
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-24.47%	Payout	-	Rel Volume	0.95	Prev Close	5.97
Sales Surprise	-	EPS Surprise	2.50%	Sales Q/Q	-	Earnings	Mar 18 AMC	Avg Volume	299.42K	Price	5.72
SMA20	-32.33%	SMA50	-10.55%	SMA200	23.07%	Trades		Volume	19,128	Change	-4.18%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-07-21	Initiated	H.C. Wainwright	Buy	$32

Apr-10-24 08:45AM	Software Segment of Global A.I. Healthcare Billion Dollar Market Expected to Have Fastest Growth (PR Newswire)
Mar-20-24 09:00AM	Global A.I. Medical Diagnostics Market Poised To Reach $3.7 Billion By 2028 (GlobeNewswire) +17.49%
Mar-19-24 09:06AM	Lantern Pharma Inc. (NASDAQ:LTRN) Q4 2023 Earnings Call Transcript (Insider Monkey) -24.80%
Mar-18-24 08:53PM	LTRN Stock Earnings: Lantern Pharma Beats EPS for Q4 2023 (InvestorPlace) +14.48%
05:32PM	Lantern Pharma Inc Reports Progress and Financials for FY 2023 (GuruFocus.com)
04:02PM	Loading…
04:02PM	Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights (Business Wire)
Mar-15-24 08:00AM	Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284 (Business Wire) +18.37%
Mar-11-24 07:30AM	Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ET (Business Wire) -23.58%
Mar-07-24 06:17AM	11 Best Artificial Intelligence Stocks Under $20 According To Hedge Funds (Insider Monkey) +21.13%
Mar-05-24 08:01AM	Lantern To Participate in H.C Wainwright & Co.s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference (Business Wire) +5.95%
Mar-04-24 08:01AM	Lantern Pharma's A.I. Platform, RADR, Surpasses 60 Billion Data Points Anticipates Reaching 100 Billion Data Points in 2024, Paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development Timelines (Business Wire) +9.40%
Feb-20-24 08:01AM	3 AI Powerhouses Predicted to Soar 500% in the Next Tech Boom (InvestorPlace)
Feb-15-24 08:01AM	Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers (Business Wire)
Jan-17-24 07:30AM	Starlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS & Brain Cancers, Announces Dr. Marc Chamberlain as Chief Medical Officer (Business Wire)
Dec-13-23 08:05AM	The 3 Most Undervalued AI Penny Stocks to Buy in December (InvestorPlace)
08:00AM	Loading…
Nov-30-23 08:00AM	FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL) (Business Wire)
Nov-10-23 11:31AM	Lantern Pharma Inc. (NASDAQ:LTRN) Q3 2023 Earnings Call Transcript (Insider Monkey) -11.53%
Nov-08-23 06:43PM	Lantern Pharma Inc (LTRN) Reports Q3 2023 Financial Results and Provides Operational Updates (GuruFocus.com)
04:01PM	Lantern Pharma Reports Third Quarter 2023 Financial Results and Operational Highlights (Business Wire)
Nov-01-23 08:00AM	Lantern Pharma to Report Third Quarter 2023 Operating & Financial Results on November 8th, 2023 at 4:30 p.m. ET (Business Wire)
Oct-24-23 04:03PM	The 7 Most Undervalued AI Penny Stocks to Buy: October 2023 (InvestorPlace)
Oct-10-23 08:00AM	Lantern Pharma to Present at the ThinkEquity Conference on October 19 at 1:30 p.m. ET (Business Wire) +10.32%
Oct-03-23 08:00AM	Lantern Pharma Announces Publication in Clinical Cancer Research Highlighting the Enhanced Efficacy of LP-184 in Glioblastoma (Business Wire) -8.23%
Sep-29-23 07:40AM	LTRN: Spotlight on LP-184 & 284 (Zacks)
Sep-25-23 08:30AM	Lantern Pharma Announces First Patient Dosed in the Phase 1 Study for LP-184 in Advanced Solid Tumors (Business Wire)
Sep-18-23 09:00AM	Lantern Pharma Receives IND Clearance from FDA Enabling Phase 1 Initiation for Drug Candidate LP-284 in Non-Hodgkins Lymphomas (Business Wire)
Sep-14-23 09:09AM	The 3 Most Undervalued Machine Learning Stocks to Buy in September 2023 (InvestorPlace)
Aug-31-23 08:00AM	Lantern Pharma to Present Data Highlighting the Anti-Tumor Potency of Drug Candidate LP-284 in Non-Hodgkins Lymphomas at the Society of Hematologic Oncology Annual Meeting (Business Wire)
Aug-28-23 05:32PM	3 AI Stocks That Still Trade Under $10 Per Share (InvestorPlace)
08:00AM	Lantern Pharma Expands AI Capabilities of RADR® Platform to Accelerate the Clinical Development of Immune Checkpoint Inhibitors (Business Wire)
06:00PM	Loading…
Aug-23-23 06:00PM	The 3 Most Undervalued Machine Learning Stocks to Buy Now: August 2023 (InvestorPlace)
Aug-14-23 08:30AM	Lantern Pharma Receives Notice of US Patent Allowance for Drug Candidate LP-184 for the Treatment of Rare Pediatric Brain Cancer, ATRT (Business Wire)
Aug-10-23 08:37AM	LTRN: 2Q:23 Quarterly Update (Zacks Small Cap Research) +7.07%
Aug-09-23 04:01PM	Lantern Pharma Reports Second Quarter 2023 Financial Results and Operational Highlights (Business Wire)
09:11AM	3 AI Penny Stocks With the Potential to Make Your Financial Dreams Come True (InvestorPlace)
Aug-08-23 03:06PM	3 AI Stocks Youll Regret Not Buying Soon (InvestorPlace)
Aug-02-23 12:45PM	RedChip Launches 'Small Stocks, Big Money' Podcast (ACCESSWIRE)
08:00AM	Lantern Pharma to Report Second Quarter 2023 Operating & Financial Results on August 9, 2023 at 4:30 p.m. ET (Business Wire)
Aug-01-23 07:30PM	3 AI Stocks to Buy Under $10 in August 2023 (InvestorPlace) +5.62%
Jul-30-23 02:45PM	7 AI Penny Stocks that Could Hit $5 Soon (InvestorPlace)
Jul-17-23 08:00AM	Lantern Pharma to Participate and Present at Multiple Upcoming Conferences (Business Wire)
Jun-26-23 08:30AM	Oncotarget Publishes New Data by Lantern Pharma, an AI Company Developing Cancer Therapies, Further Supporting Clinical Advancement of LP-284, a Novel Synthetically Lethal Drug Candidate for Non-Hodgkins Lymphomas (Business Wire)
Jun-12-23 08:30AM	Lantern Pharma Receives FDA Clearance of IND Application for Drug Candidate LP-184 in Solid Tumors (Business Wire) +7.96%
Jun-08-23 09:00AM	Lantern Pharma Leverages AI Platform, RADR®, to Develop Breakthrough Antibody Drug Conjugates (ADCs) in Collaboration with Bielefeld University (Business Wire)
May-19-23 06:50AM	3 Penny Stocks to Buy as the AI Sector Transforms Every Industry in 2023 (InvestorPlace) +6.38%
May-17-23 08:00AM	Lantern Pharma to Present at the Lytham Partners Spring 2023 Investor Conference Thursday, May 18th at 9:00 a.m. ET (Business Wire)
May-10-23 09:59AM	LTRN: First Harmonic Patient Dosed (Zacks Small Cap Research)
May-09-23 04:01PM	Lantern Pharma Reports First Quarter 2023 Financial Results and Operational Highlights (Business Wire) +5.66%
May-03-23 09:00AM	Lantern Pharma Selects REPROCELL USA to Provide Support for the Phase 2 Harmonic Clinical Trial (PR Newswire) -6.05%
May-02-23 04:01PM	Lantern Pharma to Report First Quarter 2023 Operating & Financial Results on May 9, 2023 at 4:30 p.m. ET (Business Wire)
07:30AM	Lantern Pharma Develops Top-Ranked AI Algorithms to Predict the Blood-Brain-Barrier Permeability of Any Compound (Business Wire)
Apr-13-23 07:30AM	Lantern Pharma Receives Notice of Allowance for Composition of Matter Patent Covering Drug Candidate LP-284 (Business Wire)
Mar-28-23 08:00AM	Lantern Pharma Announces First Patient Dosed in the Phase 2 Study, Harmonic, for LP-300 in Never Smokers with Advanced Non-Small Cell Lung Cancer (Business Wire)
Mar-24-23 07:15AM	Lantern Pharma Inc. (NASDAQ:LTRN) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-22-23 11:50AM	We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate (Simply Wall St.)
11:45AM	LTRN: 2022 Financial and Operational Results (Zacks Small Cap Research)
Mar-21-23 04:01PM	Lantern Pharma to Present at Upcoming Scientific Conferences and Webinars (Business Wire) -5.38%
12:11PM	Q4 2022 Lantern Pharma Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-20-23 04:01PM	Lantern Pharma Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Operational Highlights (Business Wire)
Mar-15-23 08:00AM	Lantern Pharma to Present at the American Association for Cancer Research (AACR) Annual Meeting (Business Wire)
Mar-13-23 08:00AM	Lantern Pharma to Report Fourth Quarter and Fiscal Year 2022 Operating & Financial Results on March 20, 2023 at 4:30 p.m. ET (Business Wire) +9.30%
06:16AM	Lantern Pharma said it had no exposure to SVB or Signature Bank, after stock plunged last week (MarketWatch)
06:00AM	Lantern Pharma Confirms It Had No Exposure to Silicon Valley Bank (SVB), Silvergate Bank, or Signature Bank (Business Wire)
Mar-09-23 08:00AM	Lantern Pharma Announces New Data and Development Focus for LP-100 with PARP Inhibitors (Business Wire)
Mar-08-23 08:00AM	Lantern Pharma to Host Virtual KOL Webinar on Synthetic Lethality, the Powerful Mechanism of Action Behind Several of Lanterns Drug Candidates, Featuring Zoltan Szallasi, M.D. (Business Wire)
Mar-06-23 08:00AM	Lantern Pharma Announces Formation of Starlight Therapeutics to Advance Transformative Therapies for CNS (Central Nervous System) and Brain Cancers (Business Wire)
Mar-02-23 08:00AM	Lantern Pharma Expands Clinical Leadership Team to Further Advance its Ongoing and Upcoming Clinical Trials (Business Wire)
Feb-27-23 08:00AM	Lantern Pharma and TTC Oncology Establish AI Collaboration to Expand the Clinical Development of Drug Candidate TTC-352 (Business Wire)
Feb-21-23 12:10PM	7 AI Penny Stocks That Could Skyrocket in 2023 (InvestorPlace)
Feb-15-23 08:00AM	Lantern Pharma Further Enhances Capabilities of its AI Drug Discovery Platform, RADR®, with Product Development Roadmap for the Development of Antibody Drug Conjugates (Business Wire)
Feb-01-23 04:55AM	LTRN: LP-184 & LP-284 in the Spotlight (Zacks Small Cap Research)
Jan-17-23 08:00AM	Lantern Pharma Receives Pre-IND Feedback from the FDA, Clearing a Path for Drug Candidate LP-184s Phase 1 Clinical Trial in Q2 2023 (Business Wire)
Jan-05-23 08:59AM	FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in Mantle Cell Lymphoma (Business Wire) -11.94%
Dec-31-22 06:15AM	Lantern Pharma Inc. (NASDAQ:LTRN) Q3 2022 Earnings Call Transcript (Insider Monkey)
Dec-15-22 08:00AM	Lantern Pharma Announces Positive New Data for its Drug Candidate LP-284 for Mantle Cell Lymphoma (MCL) at the American Society of Hematology (ASH) 2022 Annual Meeting (Business Wire)
Dec-13-22 08:00AM	Lantern Pharma Announces Development of Drug Candidate LP-184 for Triple Negative Breast Cancer (TNBC) at the San Antonio Breast Cancer Symposium (SABCS) (Business Wire)
Dec-02-22 01:46PM	10 Best Artificial Intelligence Stocks Under $10 (Insider Monkey)
08:00AM	Lantern Pharma to Participate at the RHK Capital Disruptive Growth Conference on December 5 at 12:00 p.m. ET (GlobeNewswire)
Nov-22-22 08:00AM	Lantern Pharma Announces Positive Data Highlighting the Anti-Tumor Potency of Drug Candidate LP-184 for Glioblastoma at the Society for Neuro-Oncology Annual Meeting (Business Wire)
Nov-08-22 04:48AM	LTRN: Harmonic Screening Underway (Zacks Small Cap Research)
Nov-07-22 04:01PM	Lantern Pharma Reports Third Quarter 2022 Financial Results and Operational Highlights (Business Wire)
Nov-02-22 08:00AM	Lantern Pharma Management to Present at Upcoming Investor Conferences in Q4 (Business Wire)
Oct-31-22 08:00AM	Lantern Pharma to Report Third Quarter 2022 Operating & Financial Results on November 7, 2022 at 4:30 p.m. ET (Business Wire)
Oct-25-22 08:00AM	Lantern Pharma to Present New Preclinical Data at Three Upcoming Scientific Conferences (Business Wire)
Oct-21-22 07:00AM	Lantern Pharma to Present at the ThinkEquity Conference on Wednesday, October 26 at 1:00 p.m. ET (Business Wire)
Oct-20-22 07:59AM	Lantern Pharma Announces Issuance of New Patent that Strengthens Patent Portfolio for Cancer Drug Candidate LP-300 (Business Wire)
Oct-13-22 10:48AM	We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate (Simply Wall St.) +5.89%
Oct-11-22 04:00PM	Lantern Pharma to Present at The MicroCap Rodeo Presents The Windy City Roundup 2022 on Wednesday, October 12 at 11:00 a.m. ET (ACCESSWIRE)
Oct-05-22 08:00AM	Lantern Pharma to Present at Upcoming Investor Conferences (Business Wire)
Sep-23-22 08:50AM	Lantern Pharma to Present Positive Preclinical Data on the Efficacy of LP-284 for Mantle Cell Lymphoma at the Society of Hematologic Oncology Annual Meeting (Business Wire)
Sep-19-22 08:50AM	Lantern Pharma to Host Virtual KOL Webinar on the Treatment of Pediatric Cancers During Childhood Cancer Awareness Month, featuring Peter Houghton, Ph.D. (Business Wire)
Sep-14-22 12:05PM	Lantern Pharma Touts Encouraging Positive Efficacy For Pancreatic Cancer Candidate (Benzinga) +5.51%
08:50AM	Lantern Pharma to Present Positive Preclinical Data on the Efficacy of LP-184 for Pancreatic Cancer at the AACR Special Conference for Pancreatic Cancer (Business Wire)
Aug-30-22 09:00AM	Lantern Pharma CEO & President, Panna Sharma, to Speak at H.C. Wainwrights 24th Annual Global Investment Conference in September 2022 (Business Wire) -6.37%
Aug-19-22 08:30AM	Lantern Pharma Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R) (ACCESSWIRE) -5.56%
Aug-09-22 08:20AM	LTRN: Music to Our Ears: Harmonic to Start (Zacks Small Cap Research)
Aug-08-22 04:01PM	Lantern Pharma Reports Second Quarter 2022 Financial Results and Operational Highlights (Business Wire)
Aug-01-22 07:00AM	Lantern Pharma to Report Second Quarter 2022 Operating & Financial Results on August 8th, 2022 at 4:30 p.m. ET (Business Wire)
Jul-14-22 07:00AM	Lantern Pharma Receives FDA Authorization to Initiate its Phase 2 Clinical Trial, Harmonic, for LP-300 in Never Smokers with Non-Small Cell Lung Cancer (Business Wire) -11.82%
May-12-22 07:00AM	Lantern Pharma to Host Virtual KOL Event on Glioblastoma Multiforme (GBM) with Collaborators from Johns Hopkins during Brain Tumor Awareness Month (PR Newswire) -8.06%

Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. Its portfolio includes LP-100, LP-300, and LP-184. The company was founded by Arun K. Asaithambi, Gregory T. Tobin, and Peter L. Nara on November 7, 2013 and is headquartered in Dallas, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kreis Leslie W.	10% Owner	Feb 29 '24	Sale	4.87	19,703	95,954	60,256	Feb 29 09:54 PM
Fletcher Aaron G.L.	10% Owner	Feb 29 '24	Sale	4.87	19,703	95,954	60,256	Feb 29 09:54 PM
Fletcher Aaron G.L.	10% Owner	Feb 28 '24	Sale	4.85	74,297	360,340	62,088	Feb 29 09:54 PM
Kreis Leslie W.	10% Owner	Feb 28 '24	Sale	4.85	74,297	360,340	62,088	Feb 29 09:54 PM
Kreis Leslie W.	10% Owner	Feb 27 '24	Sale	4.40	50,000	220,000	68,997	Feb 29 09:54 PM
Fletcher Aaron G.L.	10% Owner	Feb 27 '24	Sale	4.40	50,000	220,000	68,997	Feb 29 09:54 PM
Kreis Leslie W.	10% Owner	Jan 17 '24	Sale	4.20	58,889	247,334	73,646	Jan 19 04:30 PM
Fletcher Aaron G.L.	10% Owner	Jan 17 '24	Sale	4.20	58,889	247,334	73,646	Jan 19 04:31 PM
Kreis Leslie W.	10% Owner	Nov 29 '23	Sale	3.44	145,348	499,997	217,553	Dec 01 06:00 AM
Fletcher Aaron G.L.	10% Owner	Nov 29 '23	Sale	3.44	145,348	499,997	217,553	Dec 01 06:01 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LTRN

Lantern Pharma Inc

Upgrade your FINVIZ experience